Equities researchers at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a note issued to investors on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.
Cellectis Stock Performance
Shares of Cellectis stock opened at $2.51 on Friday. Cellectis has a one year low of $0.96 and a one year high of $3.77. The firm has a market capitalization of $139.51 million, a price-to-earnings ratio of -1.50 and a beta of 3.12. The business has a 50-day simple moving average of $2.62 and a 200 day simple moving average of $2.65. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.20 and a quick ratio of 2.20.
Cellectis Company Profile
Read More
- Five stocks we like better than Cellectis
- Trading Stocks: RSI and Why it’s Useful
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- 3 REITs to Buy and Hold for the Long Term
- MarketBeat Week in Review – 4/22 – 4/26
- The How and Why of Investing in Gold Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.